Literature DB >> 23312966

Hereditary hemorrhagic telangiectasia, liver vascular malformations and cardiac consequences.

Isabelle Ginon1, Evelyne Decullier, Gerard Finet, Jean-Francois Cordier, Denis Marion, Jean-Christophe Saurin, Sophie Dupuis-Girod.   

Abstract

BACKGROUND: HHT patients with liver vascular malformations (VMs) may develop high-output cardiac failure requiring liver transplant in few cases.
OBJECTIVE: Our aim is to show that echocardiography is a good tool to evaluate the severity of hepatic vascular malformations in HHT and can improve medical management in HHT patients.
METHODS: The study is a cross-sectional study of cardiac parameters in HHT patients with dyspnea in a single referral center. All HHT patients with dyspnea, consecutively seen at HHT reference center in Lyon between May 2007 and November 2009 were included and had hepatic vascular Ultrasound and Echocardiography. Echocardiographic measures included cardiac output (CO) and index (CI), left ventricle (LV) filling pressures, and pulmonary artery pressure. Then, patients were classified in 4 groups according to the severity: group 1 (normal values), group 2 with isolated high CI, group 3 with high CI and increased LV-filling pressures and group 4 with increased LV-filling pressures and pulmonary hypertension.
RESULTS: Fifty-two HHT-patients were analyzed. Eight patients were in group 1, 25 in group 2, 6 in group 3 and 13 in group 4. Age, NYHA class dyspnea, edema, atrial fibrillation, hepatic artery diameter, and BNP (brain natriuretic peptide) levels significantly increased from groups 1 to 4 as well as left atrial area, and presence of mitral regurgitation. Patients with associated pulmonary VMs (n=11) did not show any clinical or echocardiographic differences.
CONCLUSION: Performing echocardiography in HHT patients with dyspnea allowed us to better understand the physiological processes of high-CO failure complicating liver vascular malformations and may improve follow-up of patients and treatment decisions.
Copyright © 2012 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23312966     DOI: 10.1016/j.ejim.2012.12.013

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  10 in total

1.  Conditional knockout of activin like kinase-1 (ALK-1) leads to heart failure without maladaptive remodeling.

Authors:  Kevin J Morine; Xiaoying Qiao; Vikram Paruchuri; Mark J Aronovitz; Emily E Mackey; Lyanne Buiten; Jonathan Levine; Keshan Ughreja; Prerna Nepali; Robert M Blanton; Richard H Karas; S Paul Oh; Navin K Kapur
Journal:  Heart Vessels       Date:  2017-02-17       Impact factor: 2.037

Review 2.  ALK1 signaling in development and disease: new paradigms.

Authors:  Beth L Roman; Andrew P Hinck
Journal:  Cell Mol Life Sci       Date:  2017-09-04       Impact factor: 9.261

3.  Hereditary hemorrhagic telangiectasia (HHT): a practical guide to management.

Authors:  Adrienne M Hammill; Katie Wusik; Raj S Kasthuri
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

4.  High-Output Cardiac Failure Due to Hereditary Hemorrhagic Telangiectasia: A Case of an Extra-Cardiac Left to Right Shunt.

Authors:  Patrick R Wu; Amber Horwith; Stephanie Mai; Milind Parikh; Gaurav Tyagi; Ramdas G Pai
Journal:  Int J Angiol       Date:  2016-06-02

5.  BMP10-mediated ALK1 signaling is continuously required for vascular development and maintenance.

Authors:  Teresa L Capasso; Bijun Li; Harry J Volek; Waqas Khalid; Elizabeth R Rochon; Arulselvi Anbalagan; Chelsea Herdman; H Joseph Yost; Flordeliza S Villanueva; Kang Kim; Beth L Roman
Journal:  Angiogenesis       Date:  2019-12-11       Impact factor: 9.596

6.  Different forms of pulmonary hypertension in a family with clinical and genetic evidence for hereditary hemorrhagic teleangectasia type 2.

Authors:  Alessandra Greco; Sara Plumitallo; Laura Scelsi; Giannantonio Maggi; Matteo Sobrero; Annalisa Turco; Claudia Raineri; Natalia Arseni; Donata Cappelletti; Luigi Oltrona Visconti; Fabio Pagella; Giuseppe Spinozzi; Stefano Ghio; Carla Olivieri; Cesare Danesino
Journal:  Pulm Circ       Date:  2018-05-25       Impact factor: 3.017

7.  Hereditary hemorrhagic telangiectasia of liver: Pathophysiology with role of radiology in diagnosis and treatment.

Authors:  Maheswaran Viyannan; Devanand Balalakshmoji; Venkatakrishnan Leelakrishnan
Journal:  Indian J Radiol Imaging       Date:  2020-03-30

8.  Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia.

Authors:  C L Shovlin; C M Millar; F Droege; A Kjeldsen; G Manfredi; P Suppressa; S Ugolini; N Coote; A D Fialla; U Geisthoff; G M Lenato; H J Mager; F Pagella; M C Post; C Sabbà; U Sure; P M Torring; S Dupuis-Girod; E Buscarini
Journal:  Orphanet J Rare Dis       Date:  2019-08-28       Impact factor: 4.123

9.  Pulmonary hypertension subtypes associated with hereditary haemorrhagic telangiectasia: Haemodynamic profiles and survival probability.

Authors:  Sabine Revuz; Evelyne Decullier; Isabelle Ginon; Nicolas Lamblin; Pierre-Yves Hatron; Pierre Kaminsky; Marie-France Carette; Pascal Lacombe; Anne-Claire Simon; Sophie Rivière; Jean-Robert Harlé; Alain Fraisse; Christian Lavigne; Vanessa Leguy-Seguin; Ari Chaouat; Chahera Khouatra; Sophie Dupuis-Girod; Eric Hachulla
Journal:  PLoS One       Date:  2017-10-05       Impact factor: 3.240

10.  Subaortic Membranes in Patients With Hereditary Hemorrhagic Telangiectasia and Liver Vascular Malformations.

Authors:  Agnes S Kim; Katharine J Henderson; Sumeet Pawar; Min Jung Kim; Shahnaz Punjani; Jeffrey S Pollak; John T Fahey; Guadalupe Garcia-Tsao; Lissa Sugeng; Lawrence H Young
Journal:  J Am Heart Assoc       Date:  2020-10-15       Impact factor: 5.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.